Literature DB >> 12438940

Transgenic over-expression of galanin in injured primary sensory neurons.

Andrea Bacon1, Fiona E Holmes, Caroline J Small, Mohammed Ghatei, Sally Mahoney, Stephen Bloom, David Wynick.   

Abstract

The 29 amino acid neuropeptide galanin is normally expressed in < 5% of sensory neurons in the adult dorsal root ganglia. After nerve transection (axotomy), the galanin content of the dorsal root ganglia rises 120-fold and the peptide is then expressed in > 50% of neurons. Published data suggest that galanin plays a role in the modulation of pain processing and may be involved in the regeneration of sensory neurons. Here we describe the initial characterisation of a new line of transgenic mice that selectively over-express galanin in the dorsal root ganglia in an inducible manner following axotomy of the sciatic nerve, but not in the uninjured state. Results of acute thermal or mechanosensory pain tests are normal in intact transgenic animals when compared to wild-type controls. The generation of these novel transgenic animals will be most useful as genetic tools to further elucidate the role played by galanin in the adaptive response of the peripheral nervous system to injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438940     DOI: 10.1097/00001756-200211150-00028

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

1.  Phosphoproteomic analysis of the human pituitary.

Authors:  Sarka Beranova-Giorgianni; Yingxin Zhao; Dominic M Desiderio; Francesco Giorgianni
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Skin incision induces expression of axonal regeneration-related genes in adult rat spinal sensory neurons.

Authors:  Caitlin E Hill; Benjamin J Harrison; Kris K Rau; M Tyler Hougland; Mary Bartlett Bunge; Lorne M Mendell; Jeffrey C Petruska
Journal:  J Pain       Date:  2010-06-02       Impact factor: 5.820

Review 3.  Neuroprotective role for galanin in Alzheimer's disease.

Authors:  Scott E Counts; Sylvia E Perez; Stephen D Ginsberg; Elliott J Mufson
Journal:  Exp Suppl       Date:  2010

4.  Characterisation of the nociceptive phenotype of suppressible galanin overexpressing transgenic mice.

Authors:  Robert J P Pope; Fiona E Holmes; Niall C Kerr; David Wynick
Journal:  Mol Pain       Date:  2010-10-21       Impact factor: 3.395

5.  Transgenic overexpression of galanin in the dorsal root ganglia modulates pain-related behavior.

Authors:  Fiona E Holmes; Andrea Bacon; Robert J P Pope; Penny A Vanderplank; Niall C H Kerr; Madhu Sukumaran; Vassilis Pachnis; David Wynick
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

Review 6.  Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?

Authors:  S E Counts; S E Perez; E J Mufson
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

7.  Effects of norepinephrine on galanin expression in dorsal root ganglion neurons in vitro.

Authors:  Xiangdong Yang; Zhen Liu; Zhenzhong Li
Journal:  Curr Ther Res Clin Exp       Date:  2009-02

8.  Galanin acts as a neuroprotective factor to the hippocampus.

Authors:  Caroline R Elliott-Hunt; Barnaby Marsh; Andrea Bacon; Robert Pope; Penny Vanderplank; David Wynick
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-23       Impact factor: 11.205

9.  Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2.

Authors:  Caroline R Elliott-Hunt; Fiona E Holmes; Dean M Hartley; Sylvia Perez; Elliott J Mufson; David Wynick
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

10.  A role for galanin in human and experimental inflammatory demyelination.

Authors:  David C Wraith; Robert Pope; Helmut Butzkueven; Heidi Holder; Penny Vanderplank; Pauline Lowrey; Michael J Day; Andrew L Gundlach; Trevor J Kilpatrick; Neil Scolding; David Wynick
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.